What new treatments did Hims & Hers Health launch?
The company launched perimenopause and menopause treatment options, including personalized treatment plans and prescription medications like estradiol and progesterone.
Yanuki
ARTICLE DETAIL
Hims & Hers Health (HIMS) Shares Soaring on Perimenopause and Menopause Treatment Launch | William Shatner's Secrets to Staying Active and Full of Life at 95 | Former South Carolina QB Stephen Garcia Diagnosed with Stage 4 Colorectal Cancer | Norovirus Outbreak on Caribbean Princess Cruise Ship | HIMS Stock: New Testosterone Push Builds as GLP-1 Market Crowds | Jordan Peterson's Health Concerns and Akathisia Awareness | Fiji Grapples with Soaring HIV Cases: An Alarming Outbreak | Newborns Bleeding to Death in US: The Vitamin K Debate | Dave Coulier Reveals 45-Pound Weight Loss from Cancer Treatment | Hims & Hers Health (HIMS) Shares Soaring on Perimenopause and Menopause Treatment Launch | William Shatner's Secrets to Staying Active and Full of Life at 95 | Former South Carolina QB Stephen Garcia Diagnosed with Stage 4 Colorectal Cancer | Norovirus Outbreak on Caribbean Princess Cruise Ship | HIMS Stock: New Testosterone Push Builds as GLP-1 Market Crowds | Jordan Peterson's Health Concerns and Akathisia Awareness | Fiji Grapples with Soaring HIV Cases: An Alarming Outbreak | Newborns Bleeding to Death in US: The Vitamin K Debate | Dave Coulier Reveals 45-Pound Weight Loss from Cancer Treatment
Health / Telehealth
Hims & Hers Health (HIMS) Shares Soaring on Perimenopause and Menopause Treatment Launch
Shares of Hims & Hers Health (HIMS) experienced a surge following the announcement of new perimenopause and menopause treatment options. This move signals a significant expansion into women's health, offering personalized treatment plans an...
Key Insights
- Hims & Hers Health launched perimenopause and menopause treatment options, including estradiol and progesterone in various forms.
- The company is reportedly on track to achieve over $1 billion in annual revenue by 2026.
- Despite a recent drop due to a Bank of America report citing weakening order trends, the stock shows significant year-to-date growth.
- Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $5,662.
In-Depth Analysis
Hims & Hers Health’s shares are known for their volatility. The recent increase followed news of the launch of perimenopause and menopause treatments, which include personalized plans and hormone-replacement therapies like estradiol and progesterone available in pills, patches, and creams.
However, just five days prior, the stock dropped 6.5% due to a Bank of America report highlighting weakening order trends and a lowered fourth-quarter revenue forecast. The bank noted a 16% year-over-year decrease in orders for September, raising concerns about the company's growth. BofA Securities lowered its fourth-quarter revenue forecast to $590 million, 6.5% below consensus.
Despite these fluctuations, Hims & Hers Health is up 135% since the beginning of the year. The stock is currently trading at $59.34 per share, which is still 13.7% below its 52-week high of $68.74 from February 2025.
FAQ
What was the impact of the Bank of America report?
The report highlighted weakening order trends and a lowered fourth-quarter revenue forecast, causing the stock to drop 6.5%.
Takeaways
- Hims & Hers Health is expanding its services into women's health, which could lead to significant growth.
- The stock is volatile, so investors should be aware of potential fluctuations.
- Despite recent concerns, the company has shown substantial growth year-to-date.
Discussion
Do you think Hims & Hers Health’s expansion into women’s health will sustain its growth? Let us know!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.